About event
Dr Glenn Crocker MBE is Executive Director of Pioneer Group, a company that creates human and planetary health ecosystems through venture building and real estate. At Pioneer, Glenn is responsible for the venture building and venture investment business. Over 30 years in the industry, he has co-founded and invested in many life science companies, especially in the discovery and development services sector. As founding CEO of BioCity Group, he built a successful business that was acquired by Trinity Investment Management in 2021, providing an excellent exit for shareholders and leading to the formation of Pioneer Group. He has a D Phil in Immunology from Oxford University and qualified as a chartered accountant with EY, where he ran the UK Biotech practice. In 2014 he was awarded an MBE for services to the biotechnology industry.
Dr Glenn Crocker MBE will explore the critical elements of early stage pitches and the rigorous due diligence process. Attendees will gain valuable insights into how to effectively present preclinical research to potential investors, highlighting key factors that VCs consider when evaluating early-stage medtech, biotech and pharmaceutical ventures.
Programme
Topics will include:
- What an early-stage investor is looking for;
- Crafting compelling pitches that capture investor interest;
- Understanding the due diligence process from a venture capital perspective;
- Strategies for showcasing the scientific, commercial and financial viability of preclinical projects;
- Real-world case studies and lessons learned from successful funding rounds.
This discussion is essential for entrepeneurs, researchers and startup teams looking to secure venture capital funding for their preclinical innovations.